FDA expands indication for Boehringer Ingelheim’s Spiriva Respimat
Independent Pharmacy Conference to present strong continuing education slate
SUN PRAIRIE, Wis. — The 2017 IPC Independent Pharmacy Conference, taking place April 6-9 at the Hyatt Regency Gainey Ranch in Scottsdale, Ariz., will provide attendees up to nine hours of continuing education courses. Each course features a topic critical to independent pharmacy success and will provide important information and ideas for pharmacy owners.
Key hot topics at the event will include: business development, transition planning, guerilla marketing, US pharmaceutical market trends, profitability, a legislative update and a DEA case study.
The IPC Independent Pharmacy Conference is open to all independent pharmacies. According to IPC President and CEO Don Anderson, a primary goal of the meeting is to provide business guidance and allow pharmacy owners to learn from others whose experience can help them operate a more profitable pharmacy.
IPC is the nation's largest group purchasing organization owned by independent pharmacy, representing nearly 6,000 members. With locations in Sun Prairie and Phoenix, Ariz., IPC prides itself on providing access to the most effective programs and services to put profit back into the independent pharmacy.
FDA approves Valeant’s Siliq for plaque psoriasis
WASHINGTON — The U.S. Food and Drug Administration approved Valeant Pharmaceuticals’s Siliq (brodalumab) to treat adults with moderate-to-severe plaque psoriasis.
Siliq is administered as an injection. It is intended for patients who are candidates for systemic therapy (treatment using substances that travel through the bloodstream, after being taken by mouth or injected) or phototherapy (ultraviolet light treatment) and have failed to respond, or have stopped responding to other systemic therapies.
"Moderate-to-severe plaque psoriasis can cause significant skin irritation and discomfort for patients, and today’s approval provides patients with another treatment option for their psoriasis," said Julie Beitz, M.D., director of the Office of Drug Evaluation III in the FDA’s Center for Drug Evaluation and Research. "Patients and their health care providers should discuss the benefits and risks of Siliq before considering treatment."
Psoriasis is a skin condition that causes patches of skin redness and flaking. According to the FDA, Siliq’s safety and efficacy were established in three randomized, placebo-controlled clinical trials with a total of 4,373 adult participants with moderate-to-severe plaque psoriasis who were candidates for systemic therapy or phototherapy. More patients treated with Siliq compared to placebo had skin that was clear or almost clear, as assessed by scoring of the extent, nature and severity of psoriatic changes of the skin.